Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

被引:5
作者
Rahmel, Tim [1 ]
Asmussen, Sven [1 ]
Karlik, Jan [2 ,3 ]
Steinmann, Joerg [4 ]
Adamzik, Michael [1 ,2 ,3 ]
Peters, Juergen [2 ,3 ]
机构
[1] Univ Klinikum Knappschaftskrankenhaus Bochum, Klin Anasthesiol Intens Med & Schmerztherapie, Schornau 23-25, D-44892 Bochum, Germany
[2] Univ Duisburg Essen, Klin Anasthesiol & Intens Med, D-45122 Essen, Germany
[3] Univ Klinikum Essen, D-45122 Essen, Germany
[4] Univ Klinikum Essen, Inst Med Mikrobiol, D-45147 Essen, Germany
来源
BMC ANESTHESIOLOGY | 2017年 / 17卷
关键词
Acute respiratory distress syndrome; CAP; 30-day mortality; Liver failure; S3; guideline; Consensus guideline; ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIALS; INTENSIVE-CARE UNITS; INFECTIOUS-DISEASES; CLINICAL-TRIAL; FLUOROQUINOLONES; MANAGEMENT; MORTALITY; EPIDEMIOLOGY; METAANALYSIS;
D O I
10.1186/s12871-017-0376-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: We tested the hypothesis that moxifloxacin monotherapy is equally effective and safe as a betalactam antibiotic based combination therapy in patients with acute respiratory distress syndrome (ARDS) evoked by severe community acquired pneumonia (CAP). Methods: In a retrospective chart review study of 229 patients with adult respiratory distress syndrome (ARDS) admitted to our intensive care unit between 2001 and 2011, 169 well-characterized patients were identified to suffer from severe CAP. Patients were treated with moxifloxacin alone, moxifloxacin in combination with beta-lactam antibiotics, or with another antibiotic regimen based on beta-lactam antibiotics, at the discretion of the admitting attending physician. The primary endpoint was 30-day survival. To assess potential drug-induced liver injury, we also analyzed biomarkers of liver cell integrity. Results: 30-day survival (69% overall) did not differ (p = 0.89) between moxifloxacin monotherapy (n = 42), moxifloxacin combination therapy (n = 44), and other antibiotic treatments (n = 83). We found significantly greater maximum activity of aspartate transaminase (p = 0.048), alanine aminotransferase (p = 0.003), and direct bilirubin concentration (p = 0.01) in the moxifloxacin treated groups over the first 10-20 days. However, these in-between group differences faded over time, and no differences remained during the last 10 days of observation. Conclusions: In CAP evoked ARDS, moxifloxacin monotherapy and moxifloxacin combination therapy was not different to a betalactam based antibiotic regimen with respect to 30-day mortality, and temporarily increased markers of liver cell integrity had no apparent clinical impact. Thus, in contrast to the current S3 guidelines, moxifloxacin may also be safe and effective even in patients with severe CAP evoked ARDS while providing coverage of an extended spectrum of severe CAP evoking bacteria. However, further prospective studies are needed for definite recommendations.
引用
收藏
页数:9
相关论文
共 28 条
  • [11] Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment
    Finch, R
    Schürmann, D
    Collins, O
    Kubin, R
    McGivern, J
    Bobbaers, H
    Izquierdo, JL
    Nikolaides, P
    Ogundare, F
    Raz, R
    Zuck, P
    Hoeffken, G
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) : 1746 - 1754
  • [12] Community-acquired Haemophilus influenzae pneumonia - New insights from the CAPNETZ study
    Forstner, Christina
    Rohde, Gernot
    Rupp, Jan
    Schuette, Hartwig
    Ott, Sebastian R.
    Hagel, Stefan
    Harrison, Nicole
    Thalhammer, Florian
    von Baum, Heike
    Suttorp, Norbert
    Welte, Tobias
    Pletz, Mathias W.
    [J]. JOURNAL OF INFECTION, 2016, 72 (05) : 554 - 563
  • [13] Guideline-Concordant Antibiotic Use and Survival Among Patients With Community-Acquired Pneumonia Admitted to the Intensive Care Unit
    Frei, Christopher R.
    Attridge, Russell T.
    Mortensen, Eric M.
    Restrepo, Marcos I.
    Yu, Yifan
    Oramasionwu, Christine U.
    Ruiz, Jessica L.
    Burgess, David S.
    [J]. CLINICAL THERAPEUTICS, 2010, 32 (02) : 293 - 299
  • [14] Hoffken G, 2009, Pneumologie, V63, pe1, DOI 10.1055/s-0029-1215037
  • [15] Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
    Kuzman, Ilija
    Bezlepko, Alexandr
    Topuzovska, Irena Kondova
    Rokusz, Laszlo
    Iudina, Liudmyla
    Marschall, Hans-Peter
    Petri, Thomas
    [J]. BMC PULMONARY MEDICINE, 2014, 14
  • [16] Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors
    Leroy, O
    Saux, P
    Bédos, JP
    Caulin, E
    [J]. CHEST, 2005, 128 (01) : 172 - 183
  • [17] Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
    Mandell, Lionel A.
    Wunderink, Richard G.
    Anzueto, Antonio
    Bartlett, John G.
    Campbell, G. Douglas
    Dean, Nathan C.
    Dowell, Scott F.
    File, Thomas M., Jr.
    Musher, Daniel M.
    Niederman, Michael S.
    Torres, Antonio
    Whitney, Cynthia G.
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 44 : S27 - S72
  • [18] Risk factors of treatment failure in community acquired pneumonia:: implications for disease outcome
    Menéndez, R
    Torres, A
    Zalacaín, R
    Aspa, J
    Villasclaras, JJM
    Borderías, L
    Moya, JMB
    Ruiz-Manzano, J
    de Castro, FR
    Blanquer, J
    Pérez, D
    Puzo, C
    Gascón, FS
    Gallardo, J
    Alvarez, C
    Molinos, L
    [J]. THORAX, 2004, 59 (11) : 960 - 965
  • [19] Miravitlles M, 2008, EXPERT OPIN PHARMACO, V9, P1755, DOI [10.1517/14656566.9.10.1755, 10.1517/14656566.9.10.1755 ]
  • [20] Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock
    Rodriguez, Alejandro
    Mendia, Angel
    Sirvent, Josep-Maria
    Barcenilla, Fernando
    de la Torre-Prados, Maria Victoria
    Sole-Violan, Jordi
    Rello, Jordi
    [J]. CRITICAL CARE MEDICINE, 2007, 35 (06) : 1493 - 1499